2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
10:30 a.m. - 12:00 p.m.
MCCNO - Hall C
Technology and Procedures, Omics Technologies, Bioinformatics, Computational Biology, Biological Processes, Pathogenesis, Immune Mechanism, Molecular Biology, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Research, AML, Translational Research, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

776 Leukemia-specific oncogenic activation of the intracellular antigen CCNA1 reveals an ideal target for precision TCR-mimic CAR T-cell immunotherapy

Maya Rose Ball-Burack, MD, Mark A Mendoza, MS2, Jack H. Peplinski, MSc3, Kobe Ikegami4, Rhonda E. Ries, MA5, Derek H. Janssens, PhD6, Scott N Furlan, MD7, Brandon Hadland, MD, PhD8, Soheil Meshinchi, MD, PhD9
1 Fred Hutchinson Cancer Research Center, Seattle, Washington, United States, Seattle Children's Hospital, Seattle, Washington, United States
2 Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
3 Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
4 Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
5 Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
6 Van Andel Institute, Seattle, Washington, United States
7 Fred Hutchinson Cancer Research Center, Seattle, Washington, United States, Seattle Children's Hospital, Seattle, Washington, United States
8 Fred Hutchinson Cancer Research Center, Seattle, Washington, United States, Seattle Children's Hospital, Seattle, Washington, United States
9 Fred Hutchinson Cancer Research Center, Seattle, Washington, United States, Seattle Children's Hospital, Seattle, Washington, United States

Effective and safe cellular immunotherapy for acute leukemias remains fundamentally limited by the scarcity of leukemia-restricted antigens. While conventional CAR T-cell therapies target transmembrane antigens, intracellular proteins presented by peptide-HLA complexes represent a vastly larger repertoire of targetable molecules. We utilized our systematic transcriptomic discovery platform to identify leukemia-restricted intracellular antigens suitable for next-generation TCR-mimic CAR T-cell therapy.

Transcriptomes from 106 normal hematopoietic specimens were interrogated to define transcriptionally silent genes and systematically compared with transcriptomes from over 3,000 pediatric and young adult AML cases to identify AML-restricted intracellular targets. Candidate antigens were then evaluated across molecular leukemia subtypes, GTEx normal tissue data, engineered leukemia models, single-cell transcriptomic datasets, promoter methylation analyses, and CUT&RUN profiling to define prevalence, underlying biology and causal links to specific alterations.

Our platform identified CCNA1 as one of the highest-priority intracellular AML-restricted targets based on absent expression in normal hematopoiesis and high expression in AML. Evaluation across GTEx demonstrated minimal to no expression in normal tissue, with physiologic expression restricted to immune-privileged germline tissues, supporting a favorable therapeutic window for peptide-HLA-directed cellular immunotherapy. Among more than 3,000 AML specimens, CCNA1 was broadly expressed, with striking enrichment in biologically defined high-risk subtypes. CCNA1 expression was universal in NUP98::NSD1 AML and enriched in KMT2A-rearranged AML and high-risk cytogenetic subsets including monosomy 7 and del(5q). In a B-cell ALL data set of 790 cases, CCNA1 had marked expression in the overwhelming majority of KMT2A-rearranged B ALL (84%) and in 82% of mixed phenotype acute leukemia (MPAL). Single-cell transcriptomic profiling confirmed CCNA1 expression in NUP98::NSD1 leukemic populations, including leukemia stem/progenitor compartments, indicating that the target is maintained within disease-propagating cells.

CCNA1 expression was tightly associated with leukemia-defining genomic alterations rather than representing a nonspecific feature of malignant transformation. CRISPR-engineered KMT2A::AFF1 and KMT2A::MLLT3 leukemia models recapitulated robust CCNA1 expression following introduction of the fusion oncogene into normal cord blood CD34+ hematopoietic stem/progenitor cells, providing a causal link between the fusion oncoprotein and CCNA1 expression. Moreover, CCNA1 expression levels correlated with oncogene expression and active cell cycle gene programs in the KMT2A::AFF1 model, suggesting that more proliferative— and thus more aggressive— clones may be particularly susceptible to CCNA1-directed targeting. To further interrogate the molecular basis of CCNA1 activation, we examined CCNA1 promoter methylation and found no relationship between promoter methylation status and transcript abundance, excluding promoter methylation as a major regulatory mechanism. In contrast, CUT&RUN profiling demonstrated direct occupancy of the CCNA1 promoter by KMT2A fusion proteins, establishing CCNA1 as a transcriptional target of KMT2A-mediated leukemogenesis and providing a mechanistic basis for its stable expression in KMT2A-rearranged leukemias.

Altogether, we show that CCNA1 represents a leukemia-restricted intracellular antigen whose expression is programmed by leukemia-defining oncogenic alterations rather than serving as a passive biomarker of malignant transformation. The convergence of negligible expression throughout normal hematopoiesis and normal tissues, persistent expression within leukemia stem/progenitor cells, and direct oncogenic regulation establishes CCNA1 as a compelling target for precision peptide-HLA-directed cellular immunotherapy. These findings provide rationale for development of CCNA1-specific TCR-mimic binders as the foundation for next-generation TCR-mimic CAR T-cell therapies. Together with our clinically advancing leukemia-restricted transmembrane antigen programs targeting FOLR1 (Tarlock, ASH 2026) and CLEC2A (Kirkey, ASH 2026), this work establishes a unified discovery and translational platform spanning both intracellular and surface antigens, providing a new paradigm for precision cellular immunotherapy across high-risk acute leukemias.

Maya Rose Ball-Burack, MD: No relevant conflicts of interest to declare.